ECSP088390A - Método para la anticoncepción hormonal preventiva bajo demanda - Google Patents

Método para la anticoncepción hormonal preventiva bajo demanda

Info

Publication number
ECSP088390A
ECSP088390A EC2008008390A ECSP088390A ECSP088390A EC SP088390 A ECSP088390 A EC SP088390A EC 2008008390 A EC2008008390 A EC 2008008390A EC SP088390 A ECSP088390 A EC SP088390A EC SP088390 A ECSP088390 A EC SP088390A
Authority
EC
Ecuador
Prior art keywords
preventive
under demand
demand
hormonal anti
conception under
Prior art date
Application number
EC2008008390A
Other languages
English (en)
Spanish (es)
Inventor
Karin Schmidt-Gollwitzer
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of ECSP088390A publication Critical patent/ECSP088390A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EC2008008390A 2005-10-19 2008-04-21 Método para la anticoncepción hormonal preventiva bajo demanda ECSP088390A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005050729A DE102005050729A1 (de) 2005-10-19 2005-10-19 Verfahren zur präventiven bedarfsweisen hormonalen Kontrazeption

Publications (1)

Publication Number Publication Date
ECSP088390A true ECSP088390A (es) 2008-05-30

Family

ID=37762565

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008390A ECSP088390A (es) 2005-10-19 2008-04-21 Método para la anticoncepción hormonal preventiva bajo demanda

Country Status (13)

Country Link
US (3) US20070111976A1 (https=)
EP (1) EP1937275A1 (https=)
JP (2) JP2009512658A (https=)
KR (1) KR20080056774A (https=)
CN (1) CN101340915A (https=)
BR (1) BRPI0617683A2 (https=)
CA (1) CA2626567C (https=)
CR (1) CR9908A (https=)
DE (1) DE102005050729A1 (https=)
EC (1) ECSP088390A (https=)
GT (1) GT200800038A (https=)
HN (1) HN2008000621A (https=)
WO (1) WO2007045513A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0819571A2 (pt) * 2007-12-20 2019-09-24 Teva Womenss Health Inc "método para contracepção de emergência, pacote farmacêutico para contracepção de emergência e composição farmacêutica"
US20120129825A1 (en) * 2009-04-14 2012-05-24 Andre Ulmann Method for on-demand contraception using levonorgestrel or norgestrel
RS55331B1 (sr) * 2009-04-14 2017-03-31 Hra Pharma Lab Postupak za kontracepciju po potrebi
DE102010040299A1 (de) 2010-09-06 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Transdermale therapeutische Systeme mit kristallisationsinhibierender Schutzfolie (Release Liner)
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US9579330B2 (en) 2012-11-22 2017-02-28 Bayer Pharma Aktiengesellschaft Use and application regimen of a pharmaceutical composition containing levonorgestrel and a COX inhibitor for on-demand contraception
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9655887B2 (en) 2013-05-23 2017-05-23 Bayer Pharma Aktiengesellschaft Pharmaceutical composition and the use thereof, and application regime of said pharmaceutical composition for on-demand contraception
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5512292A (en) * 1990-10-29 1996-04-30 Alza Corporation Transdermal contraceptive formulations methods and devices
DE4229820C2 (de) * 1992-09-07 1998-12-03 Jenapharm Gmbh Pharmazeutische Zubereitung auf Gestagen-Basis
DE4405898A1 (de) * 1994-02-18 1995-08-24 Schering Ag Transdermale therapeutische Systeme enthaltend Sexualsteroide
IL115738A (en) * 1994-10-24 2002-05-23 Schering Ag Competitive progesterone antagonists for regulating female fertility as required
UA77150C2 (en) * 1999-08-31 2006-11-15 Schering Ag Use of mesoprogestins j867, j912, or j1042 for female contraception, pharmaceutical composition and kit (variants)
US7384650B2 (en) * 1999-11-24 2008-06-10 Agile Therapeutics, Inc. Skin permeation enhancement composition for transdermal hormone delivery system
WO2003093322A2 (en) * 2002-04-30 2003-11-13 The Population Council, Inc. Carrageenan based antimicrobial compositions
CA2549916C (en) * 2003-12-12 2013-09-17 Schering Aktiengesellschaft Transdermal delivery system of hormones without penetration enhancers
UA89766C2 (en) * 2003-12-12 2010-03-10 Байер Шеринг Фарма Акциенгезельшафт Transdermal delivery system of gestodene

Also Published As

Publication number Publication date
CA2626567C (en) 2013-12-03
US20080311180A1 (en) 2008-12-18
GT200800038A (es) 2009-04-01
WO2007045513A1 (de) 2007-04-26
BRPI0617683A2 (pt) 2011-08-02
JP2014001239A (ja) 2014-01-09
JP2009512658A (ja) 2009-03-26
CA2626567A1 (en) 2007-04-26
KR20080056774A (ko) 2008-06-23
DE102005050729A1 (de) 2007-04-26
US20130089574A1 (en) 2013-04-11
EP1937275A1 (de) 2008-07-02
CR9908A (es) 2008-05-21
US20070111976A1 (en) 2007-05-17
CN101340915A (zh) 2009-01-07
HN2008000621A (es) 2011-07-22

Similar Documents

Publication Publication Date Title
ECSP088390A (es) Método para la anticoncepción hormonal preventiva bajo demanda
HN2001000266A (es) Agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis.
AR078247A1 (es) Vacuna de pcsk9
CL2008003827A1 (es) Composicion para tabletas de desintegracion oral que comprende al menos una droga ( temazepam), 0,5-3% de un polimero aglutinanete para odt, un alcohol de azucar y/o sacarido, y un desintegrante; metodo para prepararla; util para tratar una enfermedad o condicion como un trastorno del sueño en pacientes con disfagia..
CL2007001724A1 (es) Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1
ECSP045069A (es) Uso de flibanserina en el tratamiento de trastornos sexuales
CR7022A (es) Productos esteroides hormonales y metodos para su preparacion
ECSP088504A (es) Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopáusicos
AR048833A1 (es) Procedimiento para el tratamiento de trastornos premenstruales y otros trastornos sexuales femeninos
CL2012000348A1 (es) Metodo para tratar o reducir la gravedad de la osteoporosis u osteopenia en un paciente que comprende administrarle el compuesto n-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-dihidro-4-oxoquinolina-3-carboxamida o una sal del mismo; composicion farmaceutica.
UY30333A1 (es) Uso de flibanserina para el tratamiento de trastornos posmenopausicos del deseo sexual
ECSP10010295A (es) Formulacion de anticuerpo
AR032204A1 (es) Complejos de inclusion de ciclodextrina-drospirenona
GT200900090A (es) Uso de valerato de estradiol o 17b-estradiol en combinacion con dienogest en una terapia oral para mantener y/o incrementar la libido femenina
CR10259A (es) Metodos para la prevencion y tratamiento de condiciones que surgen de deficiencia de estrogeno local
JOP20200260B1 (ar) مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
ECSP045029A (es) Composiciones de valdecoxib de disgregación intraoral
CO6531485A2 (es) Composiciones farmacéuticas sólidas que contienen un inhibidor de la integrasa
AR054525A1 (es) Composiciones y metodos para eltratamiento de sintomas relacionados con el ciclo
UA122873C2 (uk) Контрацептивний засіб на основі дроспіренону для пацієнтки, що страждає від надлишкової маси тіла
UA95447C2 (ru) Способ женской контрацепции
CO2019000604A2 (es) Composición vaginal que comprende una combinación de estrógeno y vitamina d
PL1845957T3 (pl) Sposób uzyskiwania ekstraktu leku zawierającego hydroksystylben
CL2008000999A1 (es) Composicion farmaceutica que comprende drospirenona y 17beta estradiol; kit farmaceutico que comprende a dicha composicion, util para terapia hormonal y contracepcion en mujeres.
CU20080067A7 (es) Método para la anticoncepción hormonal preventiva bajo demanda